Published: Employers Health 2015
With the recent approval of Addyi (flibanserin) for the sudden and unexplained loss of libido for premenopausal women, plan sponsors must weigh clinical and legal considerations. There are very important questions over Addyi’s low efficacy, concerning side effects, and the potential for gender discrimination.
Through education programs, benchmarking surveys and networking opportunities, members can REALIZE their potential to implement cutting-edge benefit strategies.
With our collective strategy programs, members’ unique strategies are MAXIMIZED through the use of group purchasing solutions.
Data analytics and advisor solutions help plan sponsors ADVANCE their benefit strategies and organizational performance.
Plan sponsors can ACCELERATE their strategies to deliver comprehensive health benefits through a trusted team of advisors encouraging a culture of health.